Dermapharm Holding SE (DMPHF)
47.69
0.00 (0.00%)
USD |
OTCM |
Oct 06, 16:00
Dermapharm Debt to Equity Ratio : 2.178 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.178 |
| March 31, 2026 | 1.407 |
| December 31, 2025 | 1.515 |
| September 30, 2025 | 1.557 |
| June 30, 2025 | 1.660 |
| March 31, 2025 | 1.559 |
| December 31, 2024 | 1.621 |
| September 30, 2024 | 1.757 |
| June 30, 2024 | 1.955 |
| March 31, 2024 | 1.769 |
| December 31, 2023 | 2.004 |
| September 30, 2023 | 2.008 |
| June 30, 2023 | 2.109 |
| March 31, 2023 | 1.957 |
| December 31, 2022 | 0.9715 |
| September 30, 2022 | 1.194 |
| June 30, 2022 | 1.400 |
| March 31, 2022 | 1.091 |
| Date | Value |
|---|---|
| December 31, 2021 | 1.167 |
| September 30, 2021 | 1.422 |
| June 30, 2021 | 1.690 |
| March 31, 2021 | 1.691 |
| December 31, 2020 | 1.885 |
| September 30, 2020 | 2.089 |
| June 30, 2020 | 2.266 |
| March 31, 2020 | 1.828 |
| December 31, 2019 | 1.990 |
| September 30, 2019 | 2.025 |
| June 30, 2019 | 2.065 |
| March 31, 2019 | 1.807 |
| December 31, 2018 | 1.206 |
| September 30, 2018 | 1.279 |
| June 30, 2018 | 1.479 |
| March 31, 2018 | 1.606 |
| December 31, 2017 | 3.457 |
| September 30, 2017 | 4.012 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| AstraZeneca PLC | 0.7166 |
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
| Veru, Inc. | 0.0945 |
| Avadel Pharmaceuticals Plc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.564B |
| Total Liabilities (Quarterly) | 1.954B |
| Shareholders Equity (Quarterly) | 613.63M |
| Current Ratio | 1.712 |
| Net Debt Paydown Yield | -1.99% |